Kayali Majd, Jaoude Joseph Abi, Ramia Paul, Assi Hazem, Geara Fady, Poortmans Philip, Zeidan Youssef H
Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Co-first authors with equal contribution.
Ecancermedicalscience. 2021 Mar 1;15:1194. doi: 10.3332/ecancer.2021.1194. eCollection 2021.
Radiation therapy is an integral part in the management of breast cancer after breast conservative surgery. In selected patients at high risk for local recurrence (LR), a boost radiation dose is commonly applied to the tumour bed.
We performed a review of the English literature using PubMed, Medline and Google Scholar for published manuscripts addressing the effect of boost radiation in breast cancer patients, focusing mainly on LR and overall survival (OS).
A total of seven studies were included in our review. Most studies (6/7, 85.7%) showed a significant improvement in local control independent of age (hazard ratios ranging between 0.34 and 0.73), with the largest absolute benefit in younger patients. None of the studies, however, was able to demonstrate an improvement in OS.
With lack of sufficient studies addressing the role of boost radiation, individualised treatment decisions are recommended, taking into account the risk factors for LR, including tumour biology. Real-life data are sorely needed to better assess the role of tumour bed boost in the contemporary era.
放射治疗是保乳手术后乳腺癌治疗不可或缺的一部分。对于局部复发(LR)高危的特定患者,通常会对瘤床给予追加放疗剂量。
我们使用PubMed、Medline和谷歌学术对英文文献进行了综述,以查找已发表的探讨追加放疗对乳腺癌患者影响的手稿,主要关注局部复发和总生存期(OS)。
我们的综述共纳入了7项研究。大多数研究(6/7,85.7%)显示,无论年龄如何,局部控制均有显著改善(风险比在0.34至0.73之间),年轻患者的绝对获益最大。然而,没有一项研究能够证明总生存期有所改善。
由于缺乏足够的研究来探讨追加放疗的作用,建议根据包括肿瘤生物学在内的局部复发风险因素做出个体化治疗决策。迫切需要实际数据来更好地评估当代瘤床追加放疗的作用。